Skip to main content

Advertisement

SpringerLink
Log in

Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients

  • Short Communication
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

The aim of this pilot study was to examine the pharmacokinetics of atazanavir (ATV) when given in combination with amprenavir (APV) or saquinavir hard-gel capsules (SQV) to human immunodeficiency virus (HIV)-positive patients.

Methods

Included in the study were 34 HIV-infected patients enrolled in the ATV Early Access Program, who were treated with unboosted ATV alone (group 1) or with the double protease inhibitor combinations, ATV plus APV (group 2) or ATV plus SQV (group 3). ATV was given at a daily dose of 400 mg q.d. with the morning meal with SQV 1200 mg per day or APV 1200 mg per day. Serial blood samples for steady-state ATV pharmacokinetics were collected before the morning dose and at 1, 2, 3, 6, 8 and 24 h post-dosing. ATV plasma concentrations were measured using a high-performance liquid chromatography method with ultraviolet detection.

Results

Of the patients, 12 received ATV as a single protease inhibitor; 12 received ATV in combination with APV; and 10 in combination with SQV. Geometric mean (coefficient of variation) ATV Ctrough was 110 ng/ml (2.38), 86 ng/ml (0.84) and 149 ng/ml (2.01) in groups 1, 2 and 3, respectively. ATV Ctrough in both double protease inhibitor combination regimens was not significantly different from that as a single protease inhibitor [geometric mean ratio (GMR): 0.77; 95% confidence interval (CI): 0.38–1.58, P=not significant for group 2 versus group 1 and 1.34, 0.40–4.49, P=not significant, for group 3 versus group 1). Patients treated with ATV plus APV had a 40.2% lower ATV Cmax and a 30.8% smaller ATV AUC than the reference group treated with unboosted ATV alone: both these differences were statistically significant (GMR, 95% CI: 0.59, 0.41–0.85, P=0.005 and 0.69, 0.48–0.99, P=0.056, respectively). No difference was observed for either Cmax or AUC between the group treated with ATV plus SQV and the reference group (GMR, 95% CI: 0.78, 0.47–1.30, P=not significant and 1.24, 0.73–2.10, P=not significant, respectively).

Conclusion

ATV pharmacokinetics does not seem to be influenced by the concomitant administration of SQV, whereas APV significantly lowers plasma ATV levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Canta F, Marrone R, Gonzalez de Requena D, Sciandra M, D’Avolio A, Bonora S, Veronese L, Caci A, Di Perri G (2004) Pharmacokinetics (PK) of atazanavir (ATV) alone and coadministered with saquinavir hard gel (SQVHG) once daily. In: Proceedings of the fifth international workshop on clinical pharmacology of HIV therapy, 1–3 April 2004, Rome, Italy (Abstract 33). http://www.virology-education.com

  2. Corbett AH, Eron JJ, Fiscus S, Rezk NL, Kashuba AD (2004) The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. JAIDS 36(4):921–928

    PubMed  Google Scholar 

  3. De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Hoetelmans R, Cauda R (2004) Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. JAIDS 35(4):359–336

    PubMed  Google Scholar 

  4. Guffanti M, De Pascalis CR, Seminari E, Fusetti G, Gianotti N, Bassetti D, Galli A, Castagna A, Lazzarin A (2003) Pharmacokinetics of amprenavir given once or twice a day when combined with ATV in heavily pre-treated HIV-positive patients. AIDS 5;17(18):2669–2671

    Google Scholar 

  5. Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C, Calligaris F, Abraham B, Pialoux G, Girard PM, Jaillon P, Rozenbaum W (2003) High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 47(3):986–990

    Article  PubMed  Google Scholar 

  6. Goldsmith D, Perry C (2003) Atazanavir. Drugs 63(3):1679–1693

    PubMed  Google Scholar 

  7. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ et al (2002) Dual versus single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 288(2):169–180

    Article  PubMed  Google Scholar 

  8. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW (2001) Induction of p-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29:754–760

    PubMed  Google Scholar 

  9. Kruse G, Stocker H, Breske A, Arasteh K, Plettenberg A, Staszewski S, Kurowski M (2004) Trough levels of six different atazanavir regimens in HIV-infected patients. In: Proceedings of the fifth international workshop on clinical pharmacology of HIV therapy, 1–3 April 2004, Rome, Italy (Abstract 49) http://www.virology-education.com

  10. La Porte C, Wasmuth J, Schneider K, Rockstroh J, Burger D (2003) Lopinavir/ritonavir plus SQV in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 17(11):1700–1702

    Article  PubMed  Google Scholar 

  11. Mauss S, Guenther S, Dieter K (2002) Unfavourable interaction of APV and lopinavir in combination with ritonavir?. AIDS 16(2):296–297

    Article  PubMed  Google Scholar 

  12. Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Olivier L, Wright A (1999) Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem 45:9, 1465–1476

    Google Scholar 

  13. O’Mara E, Mummaneni V, Randall D, Sagali N, Olsen S, Tanner T, Schuster A, Raymond R, Kaul S (2000) BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects. In: Proceedings of the seventh conference on retroviruses and opportunistic infections; January 30–February 2, 2000; San Francisco (Abstract 504) http://www.retroconference.org

  14. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB (2002) Effect of coadministration of nelfinavir, indinavir, and SQV on the pharmacokinetics of APV. Clin Pharmacol Ther 72(2):133–141

    Article  PubMed  Google Scholar 

  15. Robinson BS, Riccardi KA, Gong Y, Guo Q, Stock Da, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF (2000) BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 44(8):2093–2099

    Article  PubMed  Google Scholar 

  16. Seminari E, Schira G, Guffanti M, Dorigatti F, Soldarini A, Gentilini L, Castagna A, Lazzarin A (2003) Pharmacokinetics (PK) of saquinavir-hard gel capsules (SQV-hgc) when combined with atazanavir (ATV) as once a day combination (1200/400) in highly experienced HIV-positive patients. In: Proceedings of the second IAS conference on HIV pathogenesis and treatment, 13–17 July, 2003, Paris, (Abstract 847) http://www.ias2003.org

  17. Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Moraud-Joubert L, Chene G, Clavel F, Girard PM (2004) Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 75(4):310–323

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Disease Department, San Raffaele Scientific Institute, Vita-Salute University, Via Stamira d’Ancona 20, 20122, Milan, Italy

    Elena Seminari, Monica Guffanti, Nicola Gianotti, Giuliana Fusetti, Andrea Galli, Antonella Castagna & Adriano Lazzarin

  2. Pharmacology Department, IRCCS Policlinico S. Matteo, Pavia, Italy

    Paola Villani, Maria Cusato & Mario Regazzi

Authors
  1. Elena Seminari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Guffanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Villani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicola Gianotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Cusato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuliana Fusetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Galli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonella Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mario Regazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Adriano Lazzarin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seminari, E., Guffanti, M., Villani, P. et al. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol 61, 545–549 (2005). https://doi.org/10.1007/s00228-005-0966-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0966-x

Keywords

Search

Navigation